TY - JOUR
T1 - Immunmodulation durch pflanzliche Wirkstoffe. Doppelblindstudie an einer medizinischen Universitätsklinik am Adjuvansmodell zur Hepatitis-B-Impfung.
AU - Bostelmann, H. C.
AU - Bödeker, R. H.
AU - Dames, W.
AU - Henneicke-von Zepelin, H. H.
AU - Siegers, C. P.
AU - Stammwitz, U.
PY - 2002/1/1
Y1 - 2002/1/1
N2 - AIMS: Using the hepatitis B vaccination as a model, to investigate the extent to which the herbal immunomodulator, Esberitox N, supports seroconversion. METHOD: 346 medical students participated in the placebo-controlled, randomized double-blind study. They took 3 x 2 tablets of the test substances daily, beginning 3 days prior to the injection and ending two weeks after it. The target outcomes were seroconversion and the level of the anti-HBs titer. RESULTS: The data of 157 volunteers treated with the test substance, and 161 treated with placebo were analysed. After the first injection, the seroconversion rate was 22% in both test substance and placebo groups, and showed no advantage for the volunteers receiving the test substance. After the second injection, 89% of all members of each group revealed seroconversion. After the first injection, anti-HBs titers were appreciably higher in the test substance group (n = 34) than in the placebo group (n = 36; PWilcoxon = 0.003). The respective median values were 37.0 IU/L (95% CI: 18-68) and 15.5 IU/L (95% CI: 8-30). CONCLUSION: The immunomodulator tested has negligible influence on seroconversion, but does enhance the immune response of subjects experiencing seroconversion.
AB - AIMS: Using the hepatitis B vaccination as a model, to investigate the extent to which the herbal immunomodulator, Esberitox N, supports seroconversion. METHOD: 346 medical students participated in the placebo-controlled, randomized double-blind study. They took 3 x 2 tablets of the test substances daily, beginning 3 days prior to the injection and ending two weeks after it. The target outcomes were seroconversion and the level of the anti-HBs titer. RESULTS: The data of 157 volunteers treated with the test substance, and 161 treated with placebo were analysed. After the first injection, the seroconversion rate was 22% in both test substance and placebo groups, and showed no advantage for the volunteers receiving the test substance. After the second injection, 89% of all members of each group revealed seroconversion. After the first injection, anti-HBs titers were appreciably higher in the test substance group (n = 34) than in the placebo group (n = 36; PWilcoxon = 0.003). The respective median values were 37.0 IU/L (95% CI: 18-68) and 15.5 IU/L (95% CI: 8-30). CONCLUSION: The immunomodulator tested has negligible influence on seroconversion, but does enhance the immune response of subjects experiencing seroconversion.
UR - http://www.scopus.com/inward/record.url?scp=0037506084&partnerID=8YFLogxK
M3 - Zeitschriftenaufsätze
C2 - 12613268
AN - SCOPUS:0037506084
VL - 120
SP - 119
EP - 123
JO - Fortschritte der Medizin. Originalien
JF - Fortschritte der Medizin. Originalien
IS - 4
ER -